Evidence map›Paper›PMID 41228373›Full record

ReviewCancers2025

Enhancing Cancer Therapy with TLR7/8 Agonists: Applications in Vaccines and Combination Treatments.

Jagannath Mondal, Swayam Prabha, Thomas S Griffith, David Ferguson, Jayanth Panyam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jagannath MondalDepartment of Pharmaceutics, School of Pharmacy, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.ORCID 0000-0001-9036-2635
Swayam PrabhaDepartment of Pharmaceutics, School of Pharmacy, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.
Thomas S GriffithDepartment of Urology, Medical School, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-7205-9859
David FergusonDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-6294-8057
Jayanth PanyamDepartment of Pharmaceutics, School of Pharmacy, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195, USA.ORCID 0000-0002-8656-2244

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Targeting Toll-like receptors 7 and 8 (TLR7/8) has emerged as a promising strategy in cancer immunotherapy. TLR7/8 agonists activate robust Th1-type immune responses and bridge innate and adaptive immunity. Further, TLR7/8 agonists can serve as valuable adjuncts to conventional therapies, such as chemotherapy and radiotherapy, enhancing efficacy while reducing adverse effects. Their integration into combination regimens for cancer offers a dual advantage: amplifying antitumor immunity and reducing tumor burden. Notably, the incorporation of TLR7/8 agonists into cancer vaccine platforms has yielded encouraging results in preclinical models and is advancing toward clinical application. This review highlights the mechanisms of action, therapeutic potential, and recent progress in the development of TLR7/8 agonist-based strategies for cancer treatment. We also discuss ongoing clinical evaluations and the rationale for combining these agents with existing modalities to enable more effective, personalized, and accessible cancer therapies.

Indexed as

cancer vaccinescombination therapyimmunotherapyTLR 7/8 agonistsToll-like receptors

Identifiers

PMID41228373
PMCPMC12609206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.